Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate for Osteonecrosis in Sickle Cell Disease
NCT06016634Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Mar 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alendronate in osteonecrosis, sponsored by University of California, Davis. Primary endpoints: Recruitment and retention rates at 28 weeks, Incidence of Treatment-Emergent Adverse Events at 28 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
alendronate
03
Conditions
osteonecrosis
Beyond the preview
Go deeper on NCT06016634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06016634.